Quick Facts

Get to know us better.

Targeted Drug Delivery Technology

- Proprietary small-molecule

- Highly selective cancer and cancer stem cell targeting

- Uptake and prolonged retention in malignant cells

- Proof of concept in broad range of cancers

- Ability to attach diverse oncologic payloads

- Extensive research and peer-reviewed validation

Innovative Pipeline Through Research and Collaboration

- Radiotherapeutic, preclinical and clinical phase portfolio being developed in-house 

- Collaborating with Pierre Fabre, the third largest French pharmaceutical company, on our CLR CTX program

- Our collaboration platform will allow us to work with world class institutions to enhance our PDC Product Pipeline and will also shift risk and cost, thereby reducing shareholder risk 

Other Quick Facts


- Fiscal Year End: December 31

- Contact for Investors: investors@cellectar.com

- Contact for Media: media@cellectar.com

- Contact for Business Development: business@cellectar.com

- Contact for Patient & Physician Inquiries: clinical@cellectar.com

- General Inquiries: 608-441-8120